The γ-[[cyclodextrin]] derivative [[sugammadex]] (trade name Bridion) has been recently introduced as a novel agent to reverse the action of rocuronium.<ref name="pmid17312211">{{cite journal |author=Naguib M |title=Sugammadex: another milestone in clinical neuromuscular pharmacology |journal=Anesthesia and Analgesia |volume=104 |issue=3 |pages=575–81 |date=March 2007 |pmid=17312211 |doi=10.1213/01.ane.0000244594.63318.fc |url=http://www.anesthesia-analgesia.org/cgi/pmidlookup?view=long&pmid=17312211}}</ref> [[Sugammadex]] has been in use since 2009 in many European countries; however, it was turned down for approval twice by the US FDA due to concerns over allergic reactions and bleeding,<ref>{{cite web |last=McKee |first=Selina |title=FDA turns down Merck & Co's sugammadex again |date=September 24, 2013 |work=PharmaTimes |url=http://www.pharmatimes.com/article/13-09-24/FDA_turns_down_Merck_Co_s_sugammadex_again.aspx}}</ref> but finally approved the medication for use during surgical procedures in the United States on December 15, 2015.<ref>{{Cite web|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477512.htm|title=Press Announcements - FDA approves Bridion to reverse effects of neuromuscular blocking drugs used during surgery|website=www.fda.gov|language=en|access-date=2017-01-07}}</ref> [[Neostigmine]] can also be used as a reversal agent of rocuronium but is not as effective as sugammadex. Neostigmine is often still used due to its low cost compared with sugammadex.<ref>{{Cite journal|last=Carron|first=Michele|last2=Zarantonello|first2=Francesco|last3=Tellaroli|first3=Paola|last4=Ori|first4=Carlo|title=Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials|url=https://dx.doi.org/10.1016/j.jclinane.2016.06.018|journal=Journal of Clinical Anesthesia|volume=35|pages=1–12|doi=10.1016/j.jclinane.2016.06.018}}</ref>
